The government is ‘doubling down’ on its social media ban. But bigger penalties for platforms aren’t enough 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
France Keeps Top Health Alert as Officials Brace for Another Heatwave 
Berkshire Hathaway Cash Falls as Abel Boosts Stock Buybacks 
Hanwha Offers Up to $1.2 Billion for Austal US Business 
Venezuela Earthquake Health Risks Rise as Disease Monitoring Intensifies 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
Should I take zinc or eat oysters to ward off colds, boost my immune system or improve fertility? 
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal 
Mercedes-Benz Stock Offers Deep-Value Potential as Citi Sees Recovery Catalysts 
RFK Jr. Orders Extended Hantavirus Quarantine for Cruise Passenger 
Takeda Hit With $885M Verdict Over Amitiza Generic Drug Delay Scheme 
Natura Q2 Profit Plunges 92% as Financial Expenses Weigh on Earnings 
Trump Administration Bars U.S. Travelers From Congo Flights Amid Ebola Outbreak 
Trump Media Says Truth API Draws 10+ Customers as Conflict Concerns Grow 
Eli Lilly Eyes AtaiBeckley Acquisition to Expand Psychedelic Mental Health Pipeline 
Chinese biotech company Bliss Biopharmaceutical (BlissBio) is reportedly considering a Hong Kong initial public offering (IPO) that could raise at least $150 million, according to Bloomberg sources. The Hangzhou-based cancer drug developer is working with financial advisers to evaluate the listing, although final decisions have yet to be made and the IPO size could still change. There is also a possibility the company may postpone or cancel the plan.
Founded in 2017, BlissBio focuses on antibody-drug conjugates (ADCs) that specifically target tumors. The company currently has multiple therapies in early-stage clinical trials, including Phase 1 and Phase 2 studies, as stated on its website. ADCs are a cutting-edge treatment combining antibodies with cancer-killing agents to selectively target cancer cells, offering potential breakthroughs in oncology.
Investor interest in China's biotech sector remains strong, especially for innovative oncology firms. A recent example is Duality Biotherapeutics Inc (HK:9606), which saw its shares nearly double after its Hong Kong IPO last month, reflecting growing confidence in homegrown pharmaceutical innovation.
If successful, BlissBio’s IPO would join a wave of Chinese biotech listings on the Hong Kong Stock Exchange, which has become a favored venue for healthcare companies seeking capital to fund clinical trials and expand their R&D pipelines. With increasing demand for novel cancer therapies in China and globally, the market is watching closely to see whether BlissBio moves forward with the offering.
